Conference Series LLC extends its heartfelt welcome to “19th Euro Cancer Science and Therapy Congress” that will be held in Lisbon, Portugal during July 20-22, 2017.The conference will be organised around the theme ‘Defining an Evolved Approach towards Cancer Treatment’
Cancer Science 2017 will provide an unparalleled prospect to get associated with leading oncologists, doctors, scientists, academicians, specialists & business associates coming from all over the world. As the theme of the conference relates it serves as a global platform to converse concerning the current developments, recent advances, new approaches and future approaches in the field of cancer science & therapy.
Cancer Science & Therapy Congress 2017 conference will be organized by Conference Series LLC which is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse fields of Medical, Pharmaceutical, Clinical, Engineering, Science , Technology and Business .Cancer Science& Therapy deals with study of basic researches in the field of cancer & oncology. It involves identifying causes and to develop strategies for diagnosis, prevention, treatment and cure for this dreadful disease.
Conference Highlights
- Cancer Cell Biology
- Organ Defined Cancers
- Cancer Metastasis
- Cancer Genetics
- Cancer & Tumour Immunology
- Cancer : Genomics & Metabolomics
- Targeted Cancer Therapy
- Stem Cell Therapy
- Cancer Biomarkers
- Cancer Therapy & Treatment
- Alternative Medicine & Cancer
- Cancer Case Reports
- Novel Approaches to Cancer Therapeutics
- Precision Medicine & Cancer Therapy
- Cancer Management & Prevention
- Cancer Pharmacology
Why to attend Cancer Science 2017?
Cancer Science 2017 is the primary event that brings together a unique and international experts, researchers and decision makers both from academia and industry across the world to exchange their knowledge, expertise and research innovations in the arena of cancer treatment. During the passage of the three day conference, you can avail opportunity to both network and perceive leaders from the global academic and corporate cancer research communities
